Antigen modified cancer cell vaccines for cancer therapy

Details Antigen modified cancer cell vaccines for cancer therapy Antigen modified cancer cell vaccines for cancer therapy

2004-10-13

2008-03-25

Woitach, Joseph (Department: 1633)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C435S320100, C435S252300, C435S069300, C435S071100, C435S243000, C536S023700

Reexamination Certificate

active

07348015

ABSTRACT:
Disclosed are methods for treating cancers, particularly tumorigenic types. Cancer cells are modified to express highly immunogenic antigens so that the cells will generate a defensive response in a mammal that exhibits the cancer or is predisposed to cancer and prevent or ameliorate proliferation of cancer cells. The novel cancer cell vaccines are expected to be effective against a wide range of tumors and leukemias.

REFERENCES:
patent: 5736388 (1998-04-01), Chada et al.
patent: 6774119 (2004-08-01), Wechsler et al.
patent: 0569678 (1993-11-01), None
patent: WO 93/24136 (1993-12-01), None
patent: WO 94/21808 (1994-09-01), None
patent: WO 95/00178 (1995-01-01), None
patent: WO 95/13092 (1995-05-01), None
patent: WO 96/29093 (1996-09-01), None
patent: WO 96/36366 (1996-11-01), None
patent: WO 97/00085 (1997-01-01), None
Carbone et al., Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen?Semin Cancer Biol. Dec. 2004;14(6):399-405. Review.
Keith et al., Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. Jan. 2005;4(1):71-8. Review.
Van Dyke et al., Cell, 2002, 108: 135-144.
Tomai et al., Superantigenicity of Streptococcal M protein, 1990, The Journal of experimental medicine, 172:359-362.
Biochemistry John Wiley and Sons, 1990, 126-128.
Lawman et al., 2005, J. Immunotherapy 28:614-615 Abstract.
Avery, A.C. et al. “Activation of T Cells by Superantigen in Class II-Negative Mice”J. Immunol., 1994, pp. 4855-4861, vol. 153.
Banchereau, J. et al. “Dendritic Cells and the Control of Immunity” Nature, 1998, pp. 245-252, vol. 392.
Barratt-Boyes, S.M. et al. “Studies in a Chimpanzee Model of Dendritic Cell-Based Cancer Vaccines” Proceedings of the 87th, Annual Meeting of the American Association for Cancer, 1996, XP002039146 (abstract only).
Boyle, Michael D.P. et al. “Analysis of Genes Encoding Two Unique Type IIa Immunoglobulin G-Binding Proteins Expressed by a Single Group A Streptococcal Isolate”Infection and Immunology, 1994, pp. 1336-1347, vol. 62, No. 4.
Boyle, Michael D.P. et al. “Characterization of A Gene Coding for A Type IIo Bacterial IgG-Binding Protein”Molecular Immunology, 1995, pp. 669-678, vol. 32, No. 9.
Dellabona, Paolo et al. “Superantigens Interact With MHC Class II Molecule Outside of the Antigen Groove”Cell, 1990, pp. 1115-1121, vol. 62.
Dohlsten, M. et al. “Monoclonal Antibody-Targeted Superantigens: A Different Class of Anti-Tumor Agents”Proc. Natl. Acad. Sci. USA, 1991, pp. 9287-9291, vol. 88.
Dohlsten, M. et al. “Human Major Histocompatibility Complex Class II-Negative Colon Carcinoma Cells Present Staphylococcal Superantigens to Cytotoxic T Lymphocytes: Evidence for a Novel Enterotoxin Receptor”Eur. J. Immunol., 1991, pp. 1229-1233, vol. 21.
Dohlsten, M. et al. “Role of the Adhesion Molecule ICAM-1 (CD54) in Staphylococcal Enterotoxin-Mediated Cytotoxicity”Eur. J. Immunol., 1991, pp. 131-135, vol. 21.
Fleischer, B., et al. “T-Lymphocyte Stimulation by Microbial Superantigens”Chem. Immunol., 1992, pp. 36-64, vol. 55.
Fraser, James D. et al. “CD28 and T Cell Antigen Receptor Signal Transduction Coordinately Regulate Interleukin 2 Gene Expression in Response to Superantigen Stimulation”J. Ex. Med., 1992, pp. 1131-1134, vol. 175.
Gilboa, Eli et al., Immunotherapy of Cancer With Dendritic-Cell Based VaccinesCancer Immunol Immunother, 1998, pp. 82-87, vol. 46, No. 2.
Hartwig, Udo F. et al. “Mutations Affecting MHC Class II Binding of the Superantigen Streptococcal Erthrogenic Toxin A”International Immunology, 1993, pp. 869-875, vol. 5, No. 8.
Herman, Andrew et al. “Identification of the Staphylococcal Enterotoxin A. Superantigen Binding Site in the β1 Domain of the Human Histocompatibiity Antigen HLA-DR”,Proc. Natl. Acad. Sci. USA, 1991, pp. 9954-9958, vol. 88.
Hermann, Thomas et al. “Staphylococcal Enterotoxin-Dependent Lysis of MHC Class II Negative Target Cells by Cytolytic T Lymphocytes”,J. Immunol., 1991, pp. 2504-2512, vol. 146.
Hock, Randy A. et al. “Murine Neuroblastoma Vaccines Produced by Retroviral Transfer of MHC Class II Genes”,Cancer Gene Therapy, 1996, pp. 314-320, vol. 3, No. 5.
Johnson, Howard M. et al. “Superantigens in Human Disease”,Scientific American, 1992, pp. 92-111.
Karp, David R. et al. “The α1 Domain of the HLA-DR Molecule is Essential for High-Affinity Binding of the Toxic Shock Syndrome Toxin-1”,Nature, 1990, pp. 474-476, vol. 346.
Menard, S. et al. “Mycobacterium Tuberculosis Gene Transfer in Melanoma Cells Induces Antitumoral Immunity in Mice”Cancer Gene Therapy, 1995, p. 318, vol. 2, No. 4.
Mayordoma, J.I. et al. “Bone Marrow-Derived Dendritic Cells Pulsed With Synthetic Tumour Peptides Elicit Protective and Therapeutic Antitumour Immunity”,Nature Medicine, 1995, pp. 1297-1302, vol. 1, No. 12.
Mollick, Joseph A. et al. “Staphylococcal Exotoxin Activation of T Cells”,J. Immunology, 1991, pp. 463-468, vol. 146.
Panina-Bordignon, Paola et al. “Identification of HLA-DRα Chain Residues Critical for Binding of the Toxic Shock Sydrome Toxin Superantigen”,J. Exp. Med., 1992, pp. 1779-1784, vol. 176.
Rust, Chantal, J.J. et al. “Specific Recognition of Staphylococcal Enterotoxin A by Human T Cells Bearing Receptors With the Vy9 Region”,Nature, pp. 572-574, vol. 346, 1990.
Webb, Susan R. et al. “T-cell Activation by Superantigens”,Curr Opinion in Immun., 1994, pp. 467-475, vol. 6.
Tomai, M. et al. “Superantigenicity of Streptococcal M Protein”,J. Exp. Med., 1990, pp. 359-362, vol. 172.
Fleischer, B. et al. “Superantigens and Pseudosuperantigens of Gram-Positive Vocci”,Med. Microbiol. Immumol., pp. 108, vol. 184, 1995.
Degnan, B. et al. “Streptococcus pyogenes Type 5 M Protein is an Antigen, Not a Superantigen, for Human T Cells”,Human Immunology, 1997, pp. 206-215, vol. 53.
Esaki, Y. et al. “Role of Human Major Histocopatibility Complex DQ Molecules in Superantigenicity of Streptococcus-Derived Protein”,Infection and Immunity, 1994, pp. 1228-1235, vol. 62, No. 4.
Verma, I.M. et al. “Gene Therapy—Promises, Problems and Prospects”,Nature, 1997, pp. 239-242, vol. 389.
Gomez-Navarro, J. et al. “Gene Therapy for Cancer”,Eur. J. Cancer, 1999, pp. 867-885, vol. 35, No. 6.
Ngo, J.T. et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”,The Protein Folding Problem and Tertiary Structure Prediction, 1994, p. 433 and 492-495, Merz (ed.) Birkhauser, Boston, MA.
Chiu, T-L et al. “Optimizing Energy Potentials for Success in Protein Tertiary Structure Prediction”,Folding & Design, May 1998, pp. 223-228, vol. 3.
Orkin, S.H. et al. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, Dec. 1995, pp. 1-41.
Ross, G. et al. “Gene Therapy in the United States: A Five Year Status Report”,Human Gene Therapy, Sep. 1996, pp. 1781-1790, vol. 7.
Ostrand-Rosenberg, S. et al. “Tumor-Specific Immunity Can Be Enhanced by Transfection of Tumor Cells with Syngeneic MHC-Class-II Genes or Allogeneic MHC-Class-I Genes”,Int. J. Cancer, 1991, pp. 61-68, vol. 6.
Kalland, T. et al. “Targeting of Superantigens”,Cell Biophysics, 1993, pp. 147-164, vol. 22.
Coupar, B.E.H. et al. “A General Method for the Construction of Recombinant Vaccinia Viruses Expressing Multiple Foreign Genes”,Gene, 1988, pp. 1-10, vol. 68.
Eck, S.L. et al. “Scope of Gene Therapy”,Gene-Based Therapy, pp. 77-101, Chapter 5, 1996.
Marshall, E. “Gene Therapy's Growing Pains”,Science, Aug. 1995, pp. 1050-1055, vol. 269.
Hollingshead, S.K. et al. “Molecular Evolution of a Multigene Family in Group A Streptococci

Affiliated with

Also associated with

Rating

Antigen modified cancer cell vaccines for cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigen modified cancer cell vaccines for cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen modified cancer cell vaccines for cancer therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3961270